Figure 1

Diagrams of self-complementary adeno-associated virus 2 (scAAV2) to deliver constitutively active Rap1a (CARap1a) or only GFP driven by (A) an RPE65 promoter (scAAV2-RPE65-GFP-CARap1a and scAAV2-RPE65-GFP) or (B) a VMD2 promoter (scAAV2-VMD2-GFP-CARap1a and scAAV2-VMD2-GFP).